Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YKP10811 in IBS-C
NCT02082457Phase 2Completed
- Sponsor
- SK Chemicals
- Start
- Dec 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of relenopride in irritable bowel syndrome (IBS) (4 arms), sponsored by SK Chemicals. Primary endpoint: Abdominal pain intensity & stool frequency responder at 12 weeks. Started Dec 2013; status: completed.
02
Drugs
relenopride
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT02082457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082457.